Amwell vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 61)
Amwell logo

Amwell

ChallengerHealthcare

Telehealth

B2B telehealth infrastructure for health systems with $275M revenue; white-label digital care platform with AI Automated Care Programs for chronic disease management.

AI VisibilityBeta
Overall Score
B61
Category Rank
#120 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
61
Perplexity
59
Gemini
65

About

Amwell (American Well) is a telehealth platform company providing virtual care infrastructure for health systems, payers, employers, and government agencies — enabling digital health visits across primary care, urgent care, behavioral health, specialty care, and automated care programs. Founded in 2006 in Boston by Roy and Ido Schoenberg and listed on NYSE in 2020, Amwell generates approximately $275 million in annual revenue serving over 2,000 health systems, 80+ health plan clients, and 80+ government programs.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

61
Overall Score
90
#120
Category Rank
#2
79
AI Consensus
83
stable
Trend
stable
61
ChatGPT
92
59
Perplexity
93
65
Gemini
89
56
Claude
96
58
Grok
95

Key Details

Category
Telehealth
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Amwell
Telehealth

Integrations

Only Moderna
Amwell is classified as company. Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.